Physician profile
Peter Clark
NPI 1548616485
$7,387.22
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $242 · 2021: $402 · 2022: $412 · 2023: $16.08 · 2024: $5,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $5,914 · Food and Beverage: $16.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $5,913.93 |
| Food and Beverage | $16.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Digital Innovations LLC | $5,913.93 | 2024 | Veracity Surgical |
| Regeneron Healthcare Solutions, INC. | $375.02 | 2019-2022 | |
| Glaukos Corporation | $180.87 | 2019-2021 | |
| Alcon Vision LLC | $171.53 | 2019 | |
| Alimera Sciences, INC. | $148.41 | 2020-2023 | Iluvien |
| Genentech USA, INC. | $135.77 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $116.29 | 2021 | |
| Ivantis, INC | $106.88 | 2020 | |
| Novartis Pharmaceuticals Corporation | $71.61 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.48 | 2019 | |
| Bausch & Lomb Americas INC. | $16.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.